Möchten Sie immer auf dem neuesten Stand bleiben?

Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting

Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence

Myriad Genetics joins forces with Nobody Wants This actress Jackie Tohn

Myriad Genetics will participate in The BofA Securities 2026 Health Care Conference and Goldman Sachs 47th Annual Global Healthcare Conference.

Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance

The latest GeneSight® Mental Health Monitor from Myriad Genetics reveals that Americans feel mental health treatment isn’t designed with them in mind.

Myriad Genetics will hold its first quarter 2026 earnings conference call at 4:30 pm ET on Tuesday, May 5, 2026. Webcast at investor.myriad.com.

Myriad Genetics will share six abstracts, including two podium presentations, at the American Association for Cancer Research (AACR) Annual Meeting.

SALT LAKE CITY, April 14, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Japan’s Ministry of...

Myriad will share new data at the Society of Gynecologic Oncology (SGO) Annual Meeting April 10-13, including two oral presentations and two posters.